Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.806 EUR | -0.66% | -5.45% | -50.25% |
Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
Apr. 03 | AB Science: reconsideration possible for masitinib in ALS | CF |
Sales 2023 * | 930K 994K | Sales 2024 * | 990K 1.06M | Capitalization | 98.86M 106M |
---|---|---|---|---|---|
Net income 2023 * | -19M -20.32M | Net income 2024 * | -18M -19.25M | EV / Sales 2023 * | 106 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 99.9 x |
P/E ratio 2023 * |
-5.09
x | P/E ratio 2024 * |
-5.38
x | Employees | 89 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.05% |
Latest transcript on AB Science
1 day | -0.66% | ||
1 week | -5.45% | ||
Current month | -28.76% | ||
1 month | -29.18% | ||
3 months | -51.32% | ||
6 months | -16.97% | ||
Current year | -50.25% |
Managers | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
Chief Tech/Sci/R&D Officer | - | 18-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
Director/Board Member | 62 | 21-06-26 |
Date | Price | Change |
---|---|---|
24-04-26 | 1.806 | -0.66% |
24-04-25 | 1.818 | -6.19% |
24-04-24 | 1.938 | -0.82% |
24-04-23 | 1.954 | +1.35% |
24-04-22 | 1.928 | +0.94% |
Delayed Quote Deutsche Boerse AG, April 26, 2024 at 02:03 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- AB Stock
- A8D Stock